
## NÃ<sup>3</sup>ra Kutszegi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/458081/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. BMC Medical Genomics, 2012, 5, 42.	1.5	41
2	HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica, 2017, 102, 1578-1586.	3.5	33
3	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget, 2017, 8, 9388-9398.	1.8	33
4	Roles of Genetic Polymorphisms in the Folate Pathway in Childhood Acute Lymphoblastic Leukemia Evaluated by Bayesian Relevance and Effect Size Analysis. PLoS ONE, 2013, 8, e69843.	2.5	32
5	Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer, 2018, 18, 704.	2.6	30
6	MicroRNA-181a as novel liquid biopsy marker of central nervous system involvement in pediatric acute lymphoblastic leukemia. Journal of Translational Medicine, 2020, 18, 250.	4.4	19
7	Pharmacogenetics of anthracyclines. Pharmacogenomics, 2016, 17, 1075-1087.	1.3	16
8	Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity. PLoS ONE, 2015, 10, e0140136.	2.5	15
9	Two tagging singleâ€nucleotide polymorphisms to capture HLA ―DRB1*07:01–DQA1*02:01–DQB1*02:02 haplotype associated with asparaginase hypersensitivity. British Journal of Clinical Pharmacology, 2021, 87, 2542-2548.	2.4	5